StartsideAMGN34 • BVMF
add
Amgen Inc. BDR
Forrige sluttkurs
52,95 R$
Dagsintervall
52,95 R$ - 53,35 R$
Årsintervall
51,81 R$ - 73,92 R$
Markedsverdi
148,80 mrd. USD
Gjennomsnittlig volum
359,00
P/E-tall
-
Utbytte
-
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | juni 2025info | Endring år til år |
|---|---|---|
Omsetning | 9,18 mrd. | 9,43 % |
Driftskostnader | 3,50 mrd. | 12,82 % |
Nettoomsetning | 1,43 mrd. | 91,96 % |
Netto resultatmargin | 15,60 | 75,48 % |
Fortjeneste per aksje | 6,02 | 21,13 % |
EBITDA | 4,34 mrd. | 5,79 % |
Faktisk avgiftssats | 8,67 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | juni 2025info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 8,03 mrd. | −13,69 % |
Totale aktiva | 87,90 mrd. | −3,31 % |
Totale passiva | 80,47 mrd. | −5,31 % |
Total egenkapital | 7,43 mrd. | — |
Utestående aksjer | 538,36 mill. | — |
P/B-forhold | 3,84 | — |
Avkastning på aktiva | 8,47 % | — |
Avkastning på kapital | 11,81 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | juni 2025info | Endring år til år |
|---|---|---|
Nettoomsetning | 1,43 mrd. | 91,96 % |
Kontantstrøm fra drift | 2,28 mrd. | −7,28 % |
Kontanter fra investering | −389,00 mill. | −79,26 % |
Kontanter fra finansiering | −2,67 mrd. | −0,91 % |
Netto kontantstrøm | −782,00 mill. | −92,14 % |
Fri kontantstrøm | 220,75 mill. | −92,64 % |
Om
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
Administrerende direktør
Grunnlagt
8. apr. 1980
Hovedkvarter
Nettsted
Ansatte
28 000
